Molecular Neurodegeneration

Article	Citations
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease	258
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	211
Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease	145
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration	143
Neuropathology and molecular diagnosis of Synucleinopathies	142
Tauopathies: new perspectives and challenges	142
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease	135
TDP-43 Pathology in Alzheimer’s Disease	132
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	126
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies	126
Solving neurodegeneration: common mechanisms and strategies for new treatments	122
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry	121
Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model	120
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics	119
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology	115
METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events	114
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis	113
Cellular and pathological heterogeneity of primary tauopathies	112
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination	106
New approaches to symptomatic treatments for Alzheimer’s disease	104
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	101
Post-infection cognitive impairments in a cohort of elderly patients with COVID-19	100
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases	99
Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease	95
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia	90

The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored	82
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions	72
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives	70
The role of inflammasomes in vascular cognitive impairment	70
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications	69
Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients	68
Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain	67
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain	62
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease	61
Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer’s disease-like neuroinflammation and cognitive impairment	61
The landscape of human tissue and cell type specific expression and co-regulation of senescence genes	60
Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology	59
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	58
TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target	57
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	57
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	56
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	55
The informed road map to prevention of Alzheimer Disease: A call to arms	55
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	55
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia	53
Identification of sixteen novel candidate genes for late onset Parkinson’s disease	52
Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease	48
Alzheimer’s disease – the journey of a healthy brain into organ failure	48
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	48
Sleep and circadian rhythms in Parkinson’s disease and preclinical models	47
CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer’s disease	47
APOΕ4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis	45
A novel systems biology approach to evaluate mouse models of late-onset Alzheimer’s disease	45
BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia	44
Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain	43
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis	42
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential	42
Enhancing GABAergic signaling ameliorates aberrant gamma oscillations of olfactory bulb in AD mouse models	41
Adiponectin-mimetic novel nonapeptide rescues aberrant neuronal metabolic-associated memory deficits in Alzheimer’s disease	40
LRP1 is a neuronal receptor for α-synuclein uptake and spread	40
Knock-in models related to Alzheimer’s disease: synaptic transmission, plaques and the role of microglia	39
Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer’s disease	39
Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer’s disease	39
Human iPSC-derived astrocytes transplanted into the mouse brain undergo morphological changes in response to amyloid-β plaques	37
Anti-amyloid therapies for Alzheimer disease: finally, good news for patients	36
Culture shock: microglial heterogeneity, activation, and disrupted single-cell microglial networks in vitro	36
Tau interactome and RNA binding proteins in neurodegenerative diseases	36
Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer’s disease brains	36
Basal lamina changes in neurodegenerative disorders	35
Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model	35
The era of cryptic exons: implications for ALS-FTD	35
Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction	35
Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo	34
Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories	34
AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma	34

The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD	33
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease	33
TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation	33
Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers	32
Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD	32
Parkinson mice show functional and molecular changes in the gut long before motoric disease onset	32
Astrocyte-derived clusterin suppresses amyloid formation in vivo	31
Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy	31
Cellular stress signaling and the unfolded protein response in retinal degeneration: mechanisms and therapeutic implications	30
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease	30
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	30
FUS-ALS hiPSC-derived astrocytes impair human motor units through both gain-of-toxicity and loss-of-support mechanisms	29
Challenge accepted: uncovering the role of rare genetic variants in Alzheimer’s disease	29
Nuclear speckle specific hnRNP D-like prevents age- and AD-related cognitive decline by modulating RNA splicing	29
Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination	29
The role of ATP-binding cassette subfamily A in the etiology of Alzheimer’s disease	27
Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum	26
Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis	26
Amyloid-beta and tau pathologies act synergistically to induce novel disease stage-specific microglia subtypes	25
Increased serum QUIN/KYNA is a reliable biomarker of post-stroke cognitive decline	25
Diabetic phenotype in mouse and humans reduces the number of microglia around β-amyloid plaques	25
17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson’s disease are associated with LRRC37A/2 expression in astrocytes	25
Processing of progranulin into granulins involves multiple lysosomal proteases and is affected in frontotemporal lobar degeneration	25
Axonal energy metabolism, and the effects in aging and neurodegenerative diseases	24
Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer’s disease	23
Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease	23
Microglial inclusions and neurofilament light chain release follow neuronal α-synuclein lesions in long-term brain slice cultures	23
The route of SARS-CoV-2 to brain infection: have we been barking up the wrong tree?	23
MicroRNA-100-5p and microRNA-298-5p released from apoptotic cortical neurons are endogenous Toll-like receptor 7/8 ligands that contribute to neurodegeneration	22
CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice	22
Beyond association: successes and challenges in linking non-coding genetic variation to functional consequences that modulate Alzheimer’s disease risk	22
VCP suppresses proteopathic seeding in neurons	22
Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases	21
High dose expression of heme oxigenase-1 induces retinal degeneration through ER stress-related DDIT3	21
Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer’s disease	21
Islet amyloid polypeptide cross-seeds tau and drives the neurofibrillary pathology in Alzheimer’s disease	20
Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels	20
TDP-43 pathology is associated with increased tau burdens and seeding	20
The TGFβ/Notch axis facilitates Müller cell-to-epithelial transition to ultimately form a chronic glial scar	20
RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD	20
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	20
APOE effects on regional tau in preclinical Alzheimer’s disease	20
Sex specific molecular networks and key drivers of Alzheimer’s disease	20
Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology	20
Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy	20
Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4	20
When the infectious environment meets the AD brain	20
The role of NURR1 in metabolic abnormalities of Parkinson’s disease	20
Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease	20
Pharmacological rescue of cognitive function in a mouse model of chemobrain	20
LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions	20
Upregulation of Ca2+-binding proteins contributes to VTA dopamine neuron survival in the early phases of Alzheimer’s disease in Tg2576 mice	19
Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders	19
Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy	19
SRSF1-dependent inhibition of C9ORF72-repeat RNA nuclear export: genome-wide mechanisms for neuroprotection in amyotrophic lateral sclerosis	18
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	18
Common mouse models of tauopathy reflect early but not late human disease	18
Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue	18
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	18
Neuroprotection by WldS depends on retinal ganglion cell type and age in glaucoma	18
The gut microbiome regulates astrocyte reaction to Aβ amyloidosis through microglial dependent and independent mechanisms	18
Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid β aggregates in vivo in a mouse model of Alzheimer’s disease	17
The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	17
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer’s disease mice	17
Nuclear dynamics and stress responses in Alzheimer’s disease	17
Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays	17
Activity of Alzheimer’s γ-secretase is linked to changes of interferon-induced transmembrane proteins (IFITM) in innate immunity	17
Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans	17
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	16
Microglial lactate metabolism as a potential therapeutic target for Alzheimer’s disease	16
A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study	16
Translational molecular imaging and drug development in Parkinson’s disease	16
NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	16
Opinion: more mouse models and more translation needed for ALS	15
Cell-autonomous role of Presenilin in age-dependent survival of cortical interneurons	15
Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy	14
Multiple system atrophy: α-Synuclein strains at the neuron-oligodendrocyte crossroad	14
Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium	14
The Alzheimer’s disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130	14
TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains	14

A Trem2R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques	14
Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer’s disease	14
Dominant mutations in MIEF1 affect mitochondrial dynamics and cause a singular late onset optic neuropathy	13
Methods to investigate intrathecal adaptive immunity in neurodegeneration	13
Glial interference: impact of type I interferon in neurodegenerative diseases	13
Updates on mouse models of Alzheimer’s disease	13
SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s disease	13
ACSS2-dependent histone acetylation improves cognition in mouse model of Alzheimer’s disease	13
Differential regulation of progranulin derived granulin peptides	13
Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells	13
CD8+ T cells in neurodegeneration: friend or foe?	12
RETRACTED ARTICLE: Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4	12
An in vitro bioengineered model of the human arterial neurovascular unit to study neurodegenerative diseases	12
Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease	12
Current views on meningeal lymphatics and immunity in aging and Alzheimer’s disease	12
Remodeling Alzheimer-amyloidosis models by seeding	12
Functional microRNA targetome undergoes degeneration-induced shift in the retina	12
Anti-malaria drug artesunate prevents development of amyloid-β pathology in mice by upregulating PICALM at the blood-brain barrier	11
Optimizing detection of Alzheimer’s disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO	11
Genome-wide association study of brain biochemical phenotypes reveals distinct genetic architecture of Alzheimer’s disease related proteins	11
Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model	11
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP	11
Synaptic dysfunction of Aldh1a1 neurons in the ventral tegmental area causes impulsive behaviors	11
Mutations in α-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases	11
Leveraging the glymphatic and meningeal lymphatic systems as therapeutic strategies in Alzheimer’s disease: an updated overview of nonpharmacological therapies	11
Deletion of Socs3 in LysM+ cells and Cx3cr1 resulted in age-dependent development of retinal microgliopathy	11